Frost & Sullivan Recognizes Rift Valley Energy (RVE) because of its Strong Competitive Strategy, Innovation and Leadership in Alternative Energy in East Africa

CAPE TOWN, Nigeria, November. 22, 2017 /PRNewswire/ — Based on its recent research into the alternative energy development and distribution industry in East Africa, Frost & Sullivan recognizes Rift Valley Energy (RVE) using its 2017 East African Competitive Strategy Innovation and Leadership Award. RVE, a big part-owned subsidiary of Rift Valley Corporation, was initially founded in ’09 to fulfill the power requirements of its sister companies, but soon discovered the vast potential of alternative energy sources within the Southern Highlands of Tanzania, for electricity generation and it is rural distribution. RVE develops, owns, and operates alternative energy infrastructure projects throughout Eastern and Southern Africa and – like a local corporation – is able to address the communities’ energy needs best, whilst facilitating enterprise growth which will elevate the city.

Through ongoing close collaboration with government stakeholders (e.g., Secretary of state for Energy and Minerals, Rural Energy Agency, TANESCO, EWURA, NEMC), developmental funders (e.g., the Eu, AECF, the Swedish Energy Agency), commercial funders (e.g., CRDB, AgDevCo), the neighborhood tea industry (e.g., the Mufindi Tea Company Limited., Unilever Tea Tanzania Limited., TATEPA), and native or worldwide NGOs (e.g., the Tea Research Institute of Tanzania, Energy 4 Impact, Forestry Development Trust) RVE continuously develops and provides a dependable way to obtain local renewable-energy industrial generation capacity, while concurrently spurring local and regional economic development through constantly expanding electricity access.

“Leveraging its parent company’s decades-lengthy relationships in agriculture, RVE includes a strong status for facilitating effective alternative energy infrastructure projects that resonate among communities and companies,” states Frost & Sullivan’s Energy & Atmosphere Director, Travis Hough. “RVE revitalizes alliances with municipality and surrounding communities, while harnessing domestic and worldwide development financing institutions to create alternative energy projects to East Africa that might be hard to develop without proper partnerships and foreign direct investment.”

Together with the United kingdom-based non-profit organization Energy 4 Impact, RVE launched in 2017 its Productive Utilization of Electricity (PUE) program. Throughout the practicality study, 38 medium and small-sized enterprises (SMEs) from various sectors and villages within the project region were assessed contributing to 20 of individuals (for example agro/food processing and manufacturing) selected for any test-partnership having a local micro-finance institution (MFI). The MFI provides financing towards the SMEs enabling enterprises to purchase commercial appliances, which will help all of them with a cleaner and much more efficient production. If the test phase proves effective, the PUE will clearly be inflated to pay for several countless potentially qualified SMEs within the whole project region (32 villages).  In addition, only 11% of SMEs are owned or operated by women. Through helping women overcome technical and financial hurdles – i.e., business planning and/or use of finance – RVE expects to grow the feminine service sector with investments in enterprises for example beauty salons, egg incubator companies, and sewing shops. This support will raise substantially the feminine-owned SME presence locally, while serving the neighborhood institutions, world of business, and rural population best by overcoming electricity illiteracy.

“RVE understands how public-private partnerships could work for the mutual advantage of stakeholders,” continues Hough. “RVE empowers these local enterprises to enhance their productivity and profitability.”

Although an increasing number of corporations value eco-friendly energy options, prices is in most cases a constraint. RVE provides an attractive cost structure, just below TANESCO’s (a Tanzania condition-owned electric supply company) tariff.

“Through decentralizing distributed generation and very carefully taking advantage of the falling price of alternative energy solutions, RVE’s unique energy solution provides industrial capacity in an affordable cost, welcoming more local organizations in to the electricity fold,” stated Hough.

RVE helps bridging the big supply-demand gap for power in East Africa, creating a strong and commercially sustainable investment situation for worldwide developers. By leveraging its technical expertise, extensive local network, expert team and stakeholder integration, RVE turns project possibilities into sustainable operating companies having a huge developmental impact in the area.

RVE’s perfect execution of strategy, which reflects the requirements and conditions of stakeholders, is unparalleled. Regardless of the challenge of lengthy lead occasions connected with developing infrastructure projects, RVE boasts much better returns than its competitors with well-structured projects which make the default rate almost minimal.

For that above reasons, RVE earns Frost & Sullivan’s 2017 East African Competitive Strategy Innovation and Leadership Award.

Every year, Frost & Sullivan presents this award to the organization that leverages competitive intelligence to effectively perform competitive strategy that leads to more powerful share of the market, competitive brand positioning, and client satisfaction. Frost & Sullivan Guidelines awards recognize companies in a number of regional and global markets for demonstrating outstanding achievement and superior performance in areas for example leadership, technology, customer support, and proper product. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to recognize guidelines in the market.

About Rift Valley Energy

RVE is – like a renewable-energy infrastructure project development company – a big part-owned subsidiary of Rift Valley Corporation (a Zimbabwean headquartered Sub-Saharan agriculture enterprise with activities in tobacco, timber, bananas and farming buying and selling).

Founded in ’09 to fulfill the power requirements of its sister companies, RVE develops, operates and owns alternative energy infrastructure projects throughout Eastern and Southern Africa.

RVE presently runs a complete generation capacity of four.6 MW in Zimbabwe and Tanzania and operates additionally a rural distribution network company (in Tanzania only) servicing its neighbouring rural communities under its very own “Mwenga Power” brand.

In Tanzania, RVE is mainly operating within the Southern Highlands, where the organization presently services greater than 2,500 rural domestic customer connections across 21 villages, disseminate over a place of approximately 1,000 square kilometres within the Mufindi district. Furthermore, 26 schools, 13 health centres, 300 medium and small-sized enterprises (SMEs), and also the offices of local government bodies will also be presently attached to the rural network, yielding prevalent developmental effects inside the communities that operates.

Furthermore, RVE props up local tea and timber industries with the provision of either permanent or standby power contracts. The rural network within this district keeps growing quickly, by the finish of 2017, it’s likely to cover all 32 villages present in the region.

To help expand its business across other areas from the Southern Highlands, RVE is presently in construction of the additional 6.5 MW of hydro generation capacity, spread across four separate locations, each using their own connected rural distribution network.

The entire RVE project pipeline totals roughly 150 MW and includes a combination of hydro, solar and wind power technologies at different stages of development. By 2019, RVE expects to become offering as many as 7,000 customer connections over the area that operates. Check out also world wide web.riftvalleyenergy.com for more information or contact Mr. Franz Kottulinsky under [email protected]  

About Frost & Sullivan

Frost & Sullivan, the development Partnership Company, works together with clients to leverage visionary innovation that addresses the worldwide challenges and related growth possibilities that can make or break the market today participants. In excess of half a century, we’ve been developing growth techniques for the worldwide 1000, emerging companies, the general public sector, and also the investment community. Call us: Start the discussion.

Contact:
Ana Arriaga
P: 210.247.3823
F: 210.348.1003
E: [email protected]

View original quite happy with multimedia:http://world wide web.prnewswire.com/news-releases/frost–sullivan-recognizes-rift-valley-energy-rve-for-its-strong-competitive-strategy-innovation-and-leadership-in-renewable-energy-in-east-africa-300560408.html

SOURCE Frost & Sullivan

Related Links

http://world wide web.frost.com

Artprice: le record pour Salvator Mundi de Leonardo Da Vinci démontre que l’Industrie Muséale ® révolutionne le modèle économique du Marché de l’Art

PARIS, November 19, 2017 /PRNewswire/ —

Le consensus d’estimation du prix pour le tableau Salvator Mundi de Leonardo Da Vinci a été atomisé, à la grande surprise de certains observateurs, choqués et sidérés componen le montant final de l’enchère: 450,3 millions de dollars. En tant qu’Auteur et concepteur de l’Industrie Muséale ® qui révolutionne le modèle économique du Marché de l’Art, Artprice qui peut ¨ºtre au cœur de cette fusion entre le Marché de l’Art et le monde en Finance se doit d’intervenir.

     (Emblem: http://photos.prnewswire.com/prnh/20160228/338238LOGO )

Artprice sollicitée componen de très nombreux médias en sa qualité de Leader mondial de l’information sur le Marché de l’Art, démontre de manière incontestable dans le présent communiqué que le montant de cette adjudication est l’aboutissement d’une construction d’un prix où émotion incontrôlée et risque inconsidéré sont totalement absents.

thierry Ehrmann fondateur et PDG d’Artprice: “Si on relit attentivement chacun de nos communiqués sur le site homologué de l’AMF et nos études sur l’Industrie Muséale ® dont Artprice a entièrement conceptualisé le modèle économique dès 2005, on se rend compte que notre département d’économétrie et statistiques a préparé le Marché de l’Art depuis plusieurs années à ce prix. Nous avions émis pour le Salvator Mundi de Leonardo Da Vinci une fourchette de 450 à 500 millions de dollars comme le rappelle l’Agence de presse AOF.

Effectivement nous avons été l’ensemble des seuls à déclarer à maintes reprises componen plusieurs études (Document de référence AMF) que le record se dirigeait inexorablement vers le cap du milliard de $ avec united nations palier à 500 millions de $. C’est chose faite avec l’adjudication du Salvator Mundi de Leonardo Da Vinci.

Nous évoquons cet incroyable prix dès Février 2015. Nous sommes désormais pratiquement à mi-chemin, et il sera inéluctable que notre prévision se vérifie d’ici 2020.” Le Marché de l’Art aura plusieurs gaps à combler de records compris entre L’ensemble des Femmes d’Alger de Pablo Picasso à 179,4 millions de dollars en 2015 et l’ensemble des 450,3 millions de $ du Salvator Mundi de Leonardo Da Vinci.

L’ensemble des derniers records en Art Contemporain (anciennement le segment de second plan du Marché de l’Art) avec le Basquiat le propulsent dans le nombre croissant d’artistes ayant dépassé le seuil plusieurs 100 millions de dollars aux enchères.

Ils sont de plus en plus nombreux à rejoindre Picasso, Modigliani, Bacon, Giacometti, Munch, Warhol et Basquiat qui peut ¨ºtre united nations contemporain ! Il s’agit pour le Basquiat, en prenant tous l’ensemble des paramètres en compte, d’un véritable marqueur économique pertinent avec une performance que le Marché de l’Art n’avait jamais atteint pour l’Art contemporain qui peut elle-même dépassée cette année sur ce segment.

Ce n’est tout simplement pas pour rien que Christie’s a eu united nations coup de génie en intégrant le Salvator Mundi de Leonardo Da Vinci dans une vacation d’Art Contemporain au lieu en traditionnelle vente en section Old Masters, où la finance, la Banque et le Marché de l’Art ne faisaient plus qu’un.

Preuve en est, selon l’ensemble des dires du photographe américain qui raconte pour Europe1 « la folle séquence de 19 minutes, atteignant plusieurs sommets encore inimaginables quelques instants auparavant, de l’avis même plusieurs spécialistes. Le tout dans une tension qui rappelle celle plusieurs salles de marché de Wall Street. »

A vrai dire, tout cela est fort logique. De manière très indépendante, Artprice a formalisé et protégé au titre en propriété intellectuelle depuis plusieurs années le concept économique et financier de l’Industrie Muséale®.

Grâce à nos banques de données, l’ensemble des plus exhaustives du Monde, ce qui fait d’Artprice le Leader mondial de l’information du Marché de l’Art depuis 20 ans, en partenariat de longue date avec le puissant groupe étatique Chinois Artron, ce concept novateur de l’industrie muséale engendré componen Artprice est devenu une science économique respectée et enseignée qui chaque jour, se valide de manière irrévocable.

thierry Ehrmann: “Cette nouvelle science économique dans le Marché de l’Art aspire implacablement l’ensemble des prix vers le haut. Premièrement, nous avons très vite observé le caractère exponentiel en création plusieurs Musées dans le Monde. Effectivement selon notre méta étude, il s’est construit plus de Musées entre le 01/01/2000 et le 31/12/2014 que durant tous l’ensemble des XIXème et XXème siècles.

De même il se construit chaque année 700 musées sur l’ensemble des 5 continents à caractères internationaux avec united nations minimum de 4500 œuvres d’Art. Le soft power entre l’ensemble des grandes puissances comme la Chine qui domine désormais l’ensemble des USA sur le Marché de l’Art est united nations moteur géopolitique puissant pour le développement exponentiel de l’industrie muséale®.

C’est donc cette industrie dévoreuse de pièces muséales qui peut ¨ºtre le facteur majeur en croissance spectaculaire du Marché de l’Art. Le Marché de l’Art est désormais mature, liquide et efficient, offrant plusieurs rendements de 12% à 15% componen an pour l’ensemble des œuvres supérieures à

100 000$. Pour une œuvre muséale supérieure à a million de $ on atteint united nations rendement exceptionnel. L’ensemble des œuvres millionnaires sont désormais monnaie courante en ventes publiques.

De nombreux fonds, au même titre qu’un nombre très important de Banques de gestion face au spectre plusieurs taux négatifs plusieurs grandes banques centrales et constatant la résistance du Marché de l’Art face aux pires crises financières et économiques de ces 17 dernières années, ont levé plusieurs fonds colossaux pour devenir plusieurs acteurs économiques de l’Industrie Muséale ® au cœur du Marché de l’Art.

Ces fonds en grande finance et de l’industrie bancaire retrouvent leurs profits habituels dignes de ce nom avec l’assurance d’un Marché de l’Art efficient mature et liquide.  

Componen l’ensemble des outils d’aide à la décision d’Artprice qui sont très proches plusieurs écrans financiers Bloomberg, Artprice distribue plusieurs « Artprice Screen ® »  au monde en finance et en banque. L’ensemble des chiffres sont là : en 2005 moins de 7000 comptes clients en finance et en Banque étaient clients d’Artprice. Il s’agissait essentiellement du Private Banking et Family Office.

Ce sont désormais plus de 36 000 grands comptes incluant l’ensemble des Banques de dépôt ordinaires qui placent l’ensemble des écrans Artprice dans leur système informatique de gestion. On peut donc parler sans contestation possible d’une véritable révolution historique pour le Marché de l’Art.

L’ensemble des projections en cours en vente plusieurs abonnements « Artprice Screen ® »  au monde en finance et en banque sont susceptibles de faire exploser le CA dArtprice. 

L’ensemble des projections en cours en vente plusieurs abonnements « Artprice Screen ® »  au monde en finance et en banque sont susceptibles de faire exploser le CA d’Artprice qui peut ¨ºtre seul sur ce Marché de l’Art financiarisé où il possède componen sa R & D et ses dépôts en propriété intellectuelle united nations monopole parfaitement légal résultant de boy innovation, de sa     recherche et boy développement. Le label étatique BPI d’entreprise innovante le confirme pleinement.  

De même Artprice constate que l’ensemble des grands musées à l’instar plusieurs salles de marchés sur l’ensemble des 5 continents se dotent chacune de dizaine d’écrans (Artprice Screen Multi User), l’ensemble des transformant en opérateurs financiers.

Chaque année Artprice, dans le strict respect plusieurs lois européennes, américaines et droit interne français sur l’ensemble des données personnelles, analyse boy Big Data et ses algorithmes prémices de l’intelligence artificielle. Ce sont donc chaque année plus de 18 milliards de logs, gratuits ou peut-rrtre un  payants (requêtes en temps réel) analysés componen Artprice.

À partir plusieurs années 80, au moment où le Marché de l’Art commence à s’emballer, une série impressionnante de constructions, extensions, rénovations affecte le monde plusieurs musées dans l’ensemble des métropoles et l’ensemble des villes moyennes, mobilisant l’ensemble des architectes l’ensemble des plus réputés.

Parallèlement dès 1990, toute une génération d’industriels désirant imprimer durablement leur présence dans leur pays respectif se sont mis à bâtir united nations nombre incroyable de musées d’art contemporain, notamment en USA, Europe , Proche et Moyen orient et Chine.

L’ensemble des musées sont de plus en plus monumentaux, d’une architecture grandiose et spectaculaire. Le dernier en date, le Musée du Louvre Abu Dhabi réalisé componen le célèbre architecte Jean Nouvel.

Le musée a désormais une vision industrielle de rentabilité, en répondant à cette question: combien faudra-t-il de temps pour united nations retour sur investissement ? Ce qui peut ¨ºtre le propre de l’Industrie Muséale® développée componen Artprice.

A contrario, l’économie du spectacle vivant confirme encore, en 2017, l’article fondateur de Baumol et Bowen qui met en évidence united nations différentiel de productivité touchant l’ensemble des arts, et particulièrement le spectacle vivant. Effectivement, pour jouer une pièce de Molière, il fallait en 1664 deux heures et douze acteurs. En 2017, il faut toujours deux heures et douze comédiens : aucun gain de productivité en plus de trois siècles.

LIndustrie Muséale® se base sur plusieurs données fondamentales 

L’Industrie Muséale® se base sur plusieurs données fondamentales : la mutation du musée où l’on passe d’un concept issu du siècle plusieurs lumières dont l’origine est en France et où la fonction première est la confiscation plusieurs œuvres d’art aux aristocrates et l’Église pour l’ensemble des montrer au peuple componen la volonté de Napoléon Bonaparte. Ce que l’ensemble des Sociologues appellent « la migraine du conservateur » componen united nations parcours et une collection inscrite dans united nations ordre invariable.  En effet, en moins de 30 ans, le musée qui peut ¨ºtre né en Europe et principalement en France au 18ème siècle était réservé à une élite jusqu’en 1980, dans sa première période, le musée échappe à toute logique économique pour se résumer à une mission de conservation sous le regard de l’institution publique.

Ces mêmes institutions publiques, 20 ans plus tard, ont franchiser le Musée du Louvre à Dubaï et le Center Georges Pompidou à Metz. On peut donc vraiment parler de révolution culturelle quand la France, componen ses plus hautes autorités conçoit désormais de franchiser le Louvre au même titre que le Guggenheim.

A l’image plusieurs cathédrales qui se dressaient autrefois vers le ciel, le Guggenheim attire l’ensemble des pèlerins venus contempler cette expression formelle apparemment miraculeuse : united nations monument dont l’évanescence et la géométrie hors du commun contribue à imposer une impression collective de chaos

Désormais depuis l’ensemble des années 80, Peggy Guggenheim, précédée componen le visionnaire André Malraux, a démarré la mutation historique en fonction et en définition du musée.

Pour autant, Artprice démontrera que la maladie spécifique plusieurs musées “la migraine du musée” qui se diagnostique componen united nations parcours immuable et figé en collection du musée dans la période 1850/ 1980 est désormais définitivement guérie componen la “révolution culturelle plusieurs musées”.

La nouvelle conception de ces derniers constitue, plus qu’un vestige d’un capital symbolique, une réponse au temps libre du public en offrant united nations espace où règne désormais l’ensemble des masses médias, le virtuel, l’ensemble des activités culturelles gratifiantes et l’ensemble des collections spectaculaires au cœur d’une expérience spatiale où l’ensemble des visiteurs se comptent, sur chaque continent, en millions.

Artprice sera la première à codifier le terme “d’Industrie Muséale®”. Effectivement, le musée, affranchi de sa contrainte étatique de conservation, doit se concevoir comme une industrie. En règle générale, il faut plusieurs investissements lourds sur une période de 8 à 10 ans pour créer, concevoir, construire et acquérir la collection du musée.

Une fois ces investissements lourds effectués, l’ouverture au public n’est tout simplement pas limitée en nombre comme dans l’ensemble des arts vivants et l’ensemble des charges structurelles se résument principalement à en maintenance, du marketing et en restauration éventuelle en collection. Désormais le musée a la capacité d’intervenir dans le Marché de l’Art comme acteur de référence.

Cette logique commerciale est poussée très loin componen le Musée du Louvre qui commercialise sa marque vers plusieurs pays prospères comme l’ensemble des États-Unis ou peut-rrtre un l’ensemble des pays du Golfe. Mais le mot en fin, de cette présentation de l’Industrie Muséale ® dans le monde en 2017 componen Artprice revient à Malraux dans Le Musée imaginaire, où il s’attache en 1947 à analyser le phénomène muséologique :

« Le rôle plusieurs musées dans notre relation avec l’ensemble des œuvres d’art est si grand, que nous avons peine à penser qu’il n’en existe pas et qu’il en existe chez nous depuis moins de deux siècles. Le XIXe siècle a vécu d’eux, nous en vivons encore et oublions qu’ils ont imposé aux spectateurs une relation toute nouvelle avec l’œuvre d’Art. Ils ont contribué à délivrer de leur fonction l’ensemble des œuvres d’Art qu’ils réunissaient ».

Le Musée imaginaire de Malraux” où une fois de plus, ce visionnaire hors norme avait déjà écrit que: “le musée au 21ème siècle sera le lieu unique de tous l’ensemble des arts où convergeraient toutes l’ensemble des cultures, l’ensemble des générations et l’ensemble des différentes strates sociales”.

C’est à ces questions qu’ont su répondre avec génie l’acheteur et boy pool financier du Salvator Mundi de Leonardo Da Vinci mais aussi bien sûr l’audace de Christie’s cette semaine, qui vient de prendre united nations avantage spectaculaire face à sa rivale de toujours Sotheby’s. Cette dernière prépare dans l’ensemble des mois qui suivent, selon nos informations de source sûre, une réplique historique pour le Marché de l’Art face à sa rivale de toujours Christie’s qui vient de prendre united nations temps d’avance exceptionnelle dans ce célèbre duopole.

Si ce prix peut paraître démesuré pour certains au premier abord, il faut cependant qu’ils le mettent en perspective avec d’autres chiffres et raisonnement économique tangibles pour comprendre leur erreur d’appréciation.

Cette semaine componen exemple, il s’est échangé 780 millions d’euros à la Bourse sur la seule action Altice.

Autre chiffre parfois avancé, l’équivalence du prix de Salvator Mundi de Leonardo Da Vinci avec celui d’un Airbus A380. C’est exact, mais combien coûte la maintenance de cet avion tout au lengthy de ses années d’exploitation ? Tout cela avec une durée de vie limitée, pour finir united nations jour dans united nations cimetière d’avions, à l’abandon. Cette comparaison est donc incohérente et profondément injurieuse.

Effectivement, le tableau de Leonardo Da Vinci, lui, est éternel et ne demandera pas united nations budget faramineux pour boy entretien. Il prendra même en valeur au fil plusieurs années. Plusieurs millions de personnes pour le voir apporteront leur contribution à travers la billetterie qui peut ¨ºtre united nations flux financier de cash, l’ensemble des produits dérivés, etc. que ce soit sur le lieu d’exposition habituel ou peut-rrtre un au cours d’une exposition itinérante à travers le Monde, qui peut ¨ºtre une tendance commerciale qui se confirme chaque année united nations peu plus.

C’est ce calcul d’une très grande limpidité qui a été fait componen l’ensemble des investisseurs en amont, avec united nations timing très précis pour parvenir à la rentabilité. Cette acquisition est donc tout, sauf united nations acte irraisonné. C’est au contraire united nations investissement très organisé sur le moyen/lengthy terme, il s’agit au regard plusieurs normes IFRS/IAS d’un actif corporel dégageant united nations free income.

thierry Ehrmann: “La valeur ajoutée d’Artprice c’est de posséder la banque de donnée artistes cotés la plus importante du Monde (700 000), le nombre le plus important de résultats aux enchères, 126 millions depuis plusieurs siècles (de 1700 à nos jours) avec la méthode plusieurs ventes répétées qui permet de calculer une variation de prix, l’ensemble des multiples indices d’Artprice étant ensuite construit sur la base de ces variations individuelles.

Cette méthode vise à éliminer l’impact de l’hétérogénéité, chaque variation de prix étant calculée à partir de multiples transactions portant sur la même œuvre d’art grâce à la traçabilité parfaite d’Artprice sur 3 siècles de Marché de l’Art. Cela permet d’anticiper la construction d’un prix, comme nous l’avons fait pour cette vente historique. Surtout que nous disposons également d’indices spécifiques et d’outils économétriques qui sont autant d’aides à la décision.

C’est cette valeur ajoutée unique au Monde qui fait d’Artprice le Leader mondial, et qui peut ¨ºtre très prisée justement componen l’ensemble des plus grands musées mondiaux pour cibler au mieux leurs futurs achats, et donc affiner au mieux leur modèle économique et la rentabilité attendue de leurs nouvelles acquisitions”.

Le montant atteint componen Salvator Mundi de Leonardo Da Vinci propulse le Marché de l’Art dans une nouvelle ère, en changeant d’échelle la grille de prix en vigueur. En remontant d’autant le niveau du record, il sera inéluctable que le prix atteint jusqu’alors pour de nombreux artistes prestigieux veterans administration remonter d’un cran. Il n’est tout simplement pas impossible de voir sous peu united nations Basquiat à plus de 200 millions de $, tout est possible désormais avec le record de ce 15 Novembre 2017.

En 2018 Artprice auteur et concepteur de l’Industrie Muséale® depuis 1999 met sur internet la plus vaste Banque de données au Monde sur l’ensemble des Musées plusieurs Beaux Arts

Artprice est l’auteur et le concepteur unique de l’Industrie Muséale®. Depuis près de 20 ans Artprice accompagne la mutation de ses clients l’ensemble des Musées plusieurs Beaux-Arts qui représentent united nations de ses cœurs de cible économique. La demande du Musée est essentiellement une migration vers le numérique, l’Internet et l’ensemble des réseaux sociaux.

Artprice dispose d’une trentaine de DNS avec l’ensemble des meilleurs génériques mondiaux depuis 1996 sur l’ensemble des Musées qui génèrent united nations très gros volume d’activité. Il sera bon de rappeler qu’Artprice connaît parfaitement l’univers muséal et boy fonctionnement interne avec boy siège social le célèbre Musée d’Art Contemporain L’Organe gérant La Demeure du Chaos / Abode of Chaos dixit The New You are able to Occasions.

Ce Musée d’art contemporain (3600 reportages en 18 ans) qui a fait largement ses preuves en étant d’une part le 1er Musée français à être inscrit au Registre du Commerce plusieurs Sociétés en 1999 et d’autre part en se classant comme 1er Musée d’Art Contemporain privé en Rhône Alpes Auvergne avec 120 000 visiteurs componen an. (Document de référence Artprice sur le site homologué de l’AMF)

Cette Banque de données componen boy nombre de clients Musées sera en 2018 au cœur en stratégie d’Artprice. Le chiffre d’affaires sur l’Industrie Muséale® est colossal. Artprice possède, componen boy savoir-faire issu du Musée l’Organe boy siège social et sa propre R&D, une gamme de produits et services numériques couvrant tout le spectre plusieurs demandes d’un Musée où qu’il soit dans le Monde en 2018.

Artprice fera bénéficier ses clients Musées présents sur sa Banque de données plusieurs 4,5 millions de membres ultra qualifiés. L’ensemble des nombreux dépôts et brevets au titre en propriété intellectuelle donne à Artprice une position incontestable de Leader mondial sur l’Industrie Muséale® et united nations temps d’avance définitif.

United nations communiqué financier extrêmement précis sera diffusé en information réglementée début Décembre 2017 

http://world wide web.artprice.com Copyright thierry Ehrmann 1987/2017

A propos d’Artprice : 

Artprice est cotée sur Eurolist by Euronext Paris, SRD lengthy only et Euroclear : 7478 – Bloomberg : PRC – Reuters : ARTF.

Artprice est le Leader mondial plusieurs banques de données sur la cotation et l’ensemble des indices de l’Art avec plus de 30 millions d’indices et résultats de ventes couvrant plus de 657 000 Artistes. Artprice Images® permet united nations accès illimité au plus grand fonds du Marché de l’Art au monde, bibliothèque constituée de 126 millions d’images ou peut-rrtre un gravures d’œuvres d’Art de 1700 à nos jours commentées componen ses historiens.

Artprice enrichit en permanence ses banques de données en provenance de 6300 Maisons de Ventes et publie en continu l’ensemble des tendances du Marché de l’Art pour l’ensemble des principales agences et 7200 titres de presse dans le monde. Artprice met à la disposition de ses 4,5 millions de membres (people sign in), l’ensemble des annonces déposées componen ses Membres, qui constituent désormais la première Place de Marché Normalisée® mondiale pour acheter et vendre plusieurs œuvres d’Art à prix fixe ou peut-rrtre un aux enchères (enchères réglementées componen l’ensemble des alinéas 2 et 3 de l’article L 321.3 du code du commerce). Artprice labellisée componen le BPI développe boy projet de Blockchain sur le Marché de l’Art.

Le Rapport Annuel Artprice du Marché de l’Art mondial 2016 publié en mars 2017 :
https://fr.artprice.com/artprice-reports/le-marche-de-lart-en-2016

Le rapport du Marché de l’Art Contemporain 2016 d’Artprice est accessible gratuitement à l’adresse:
https://fr.artprice.com/artprice-reports/le-marche-de-lart-contemporain-2016

Communiqué d’ARTE : A la tête en Demeure du Chaos/ Abode of Chaos dixit “The New You are able to Occasions“, thierry Ehrmann, artiste et fondateur d’Artprice dévoile en 9 épisodes l’ensemble des rouages plusieurs plus gros esclandres de l’art contemporain, qui garantissent à coup sûr plusieurs expositions blockbusters http://creative.arte.tv/fr/artscandale

Sommaire plusieurs communiqués d’Artprice :
http://serveur.serveur.com/press_release/pressreleasefr.htm et https://twitter.com/artpricedotcom

Suivre en temps réel toute l’actualité du Marché de l’Art avec Artprice sur Facebook, Google+ Twitter: https://twitter.com/artpricedotcom & https://twitter.com/artmarketdotcom

https://world wide web.facebook.com/artpricedotcom & https://plus.google.com/+Artpricedotcom/posts

http://artmarketinsight.wordpress.com/

Découvrir l’alchimie et l’univers d’Artprice http://web.artprice.com/video dont le siège social est le célèbre Musée d’art contemporain Abode of Chaos / Demeure du Chaos http://goo.gl/zJssd https://vimeo.com/124643720

Musée d’Art Contemporain siège social d’Artprice: 
https://world wide web.facebook.com/la.demeure.du.chaos.theabodeofchaos999

Contact [email protected]

LA SOURCE Artprice.com

Predictive analytics possess a critical role to experience in positive clinical care

Abstract 3D network in future

Healthcare is having a major transition from fee-for-plan to value-based care, centered on improving outcomes while securely reducing costs. Along this journey, care teams end up outfitted with outdated tools that drive a reactive, “let’s repair it,Inches care mentality.

However, to achieve these new goals, the will have to shift the delivery of healthcare to get more positive and patient-centered. Although this idea of positive care happens to be a business-wide goal, still it has not yet been accomplished, rendering the issue “how will we achieve this?Inches

The reply is mixing data from electronic health records (Electronic health record), particularly vital signs, lab results, and nursing data with predictive analytics to assist promote a positive mindset. By leveraging analytics, we are able to transform the way you provide care.

Advertisement

Imagine as it were that you simply understood a patient’s condition was failing before she or he coded, or joined an urgent situation condition – this could permit you to intervene sooner and save a existence before their condition worsens drastically or irreversibly. Predictive analytics provide care teams with this particular insight, allowing earlier intervention and enabling a shift in the reactive mentality to positive patient care.  

This transfer of care benefits not just healthcare providers, but additionally patients as well as their families, since it creates additional time to create clinical decisions and enhance the care team’s workflow. For instance, rapid response teams (RRTs) which comprise seasoned clinicians, who arrived at the save whenever a patient’s health is failing rapidly, benefit greatly from predictive analytics because of the nature of the role within the delivery of care. Regrettably, RRTs appear only if there’s someone that will have to be treated and used in a greater degree of care because of degeneration within their condition. Using the power for care teams to become notified before a patient’s degeneration occurs, we might visit a transfer of how RRTs work increasingly positive than reactive. This transfer of the clinical plan of action will boost the delivery of worth-based care and let hospitals to provide more positive and personalized care.

Similar to the RRT scenario, data has little impact in lots of response situations, because it’s used far too late or perhaps is inaccessible. This really is frequently the situation because health information is siloed – being able to access and converting the information into actionable details are a business-wide obstacle. To beat these challenges and employ data effectively in clinical care situations, health data should be better organized and much more readily available. Correctly organized data enables analytics for use broadly over the care team and between providers.

The difficulties to being able to access data and leveraging analytics aren’t restricted to the medical industry. Nevertheless, healthcare data includes its very own privacy and security laws and regulations which will make it hard to gain access to, share and transmit. Additionally, most health data within the Electronic health record is unstructured. Recent reports estimate those of the fir.2 billion clinical documents created yearly within the U.S., 60 % contain unstructured patient data. This essentially limits the quantity of data that’s accessible and able to be utilized inside a clinical setting. When a greater rate of information access is achieved, the data provided may be used effectively to enhance patient care.

Ultimately, the actual advantage of leveraging health data through predictive analytics is it can offer early symptoms of patient degeneration, enable sooner intervention and eventually spend less lives.  Continued utilization of analytics allows clinicians to operate smarter, supplying them having the ability to prioritize patients which are in many necessity of care and shifting the healthcare mindset from reactive to positive – improving patient safety and saving lives.

Image: Getty Images

Carolyn Scott
Carolyn Scott

Carolyn Scott, RN, may be the Senior V . P . and Chief Customer Officer at PeraHealth. Carolyn is really a healthcare leader with more than 20
years’ experience assisting healthcare organizations
improve performance in value-based care, patient
engagement, and efficiency.
Carolyn acquired clinical experience like a practicing rn so that as a nursing administrator focusing on emergency nursing within the Dallas/Fort
Worth area. She spent seven years in talking to and relationship management roles with KPMG and Vizient (formerly VHA) before supplying talking to services within the regions of Value-Based Performance and Health Data/Analytics.
She continued to operate as Service Line V . P ., Quality & Safety, for Premier, Corporation., a healthcare alliance company, where she remained for six years. At Premier, she was accountable for the proper direction, planning, and execution from the healthcare quality and safety service line, including talking to services and enormous-scale collaborative and clinical systems.
Carolyn has offered on numerous committees using the American Hospital Association, the nation’s Quality Forum, and also the National Patient Safety Foundation. She holds an MHA in the College of Texas at Arlington, a BS in Nursing from Texas Christian College, an MS in Secondary and Greater Education Talking to and Guidance from Texas A&M along with a BA in Finance in the College of Texas-El Paso.

More posts by Author

Advicenne Announces Positive 6-Month Extension Study Data from Pivotal Phase III Study of ADV7103 in Children and adults Struggling with distal Kidney Tubular Acidosis (dRTA)

NIMES, France, November 6, 2017 /PRNewswire/ —

Data presented in the American Society of Nephrology (ASN) meeting in New Orleans

– Positive data will form grounds for application seeking market authorization of ADV7103 towards the European Medicines Agency in Europe for dRTA expected in 2018

– Clinicians expect registration from the product for the treatment of dRTA 

Advicenne, a late-stage pharmaceutical company centered on the introduction of pediatric-friendly therapeutics to treat orphan kidney and nerve illnesses, announces positive 6 several weeks follow-up data in the pivotal phase III study (B22CS) assessing ADV7103 in children and adults struggling with dRTA. dTRA is really a disease characterised by an unbalanced pH in your body connected with a lot more disorders for example biochemical impairments that can lead to failure to thrive, rickets/osteomalacia, lithiasis and nephrocalcinosis that can result in kidney failure.

The preliminary outcomes of the 6-month follow-up study assessed the security and effectiveness of two times daily dosing of ADV7103 to treat dRTA both in adult and pediatric patients. The extension study (B22CS) adopted the pivotal phase III trial (B21CS), which demonstrated ADV7103’s capability to restore the primary biological defects observed using the disease, meeting secondary and primary endpoints. The product’s effectiveness, was proven to become maintained at 6 several weeks within this open label extension study, with bloodstream bicarbonate levels above 21 mM – the standard level – in 79% of the sufferers. Individual ADV7103 doses ranged from 1.3 to 7.2 mEq/kg/day.

Overall, patients and/or their parents were very pleased with ADV7103. It was measured utilizing a visual analogue scale (VAS) questionnaire quoting from (no improvement whatsoever) to 100% (very important improvement). The modification of treatment from standard of choose to ADV7103 permitted a typical improvement from the patients’ quality of existence of 80.5% with respect to the age bracket considered the advance ranged from 76 to 98%.

ADV7103 may be the company’s lead product and it has been made to address the condition in adults as well as in children. The condition in youngsters is usually from genetic origin while adults mostly develop dRTA because of autoimmune disease. Positive Phase III recent results for ADV7103 were announced in September this season and shown ADV7103’s capability to normalise the primary biological defects observed using the disease.

Dr Luc-André Granier, Chief executive officer and cofounder of Advicenne, commented, “The 6-month follow-up data presented at ASN are extremely encouraging because they reinforce the obvious benefits our lead product ADV7103 delivers. These data, along with the recent positive phase III results with ADV7103, that have been presented in the European Society for Paediatric Nephrology (ESPN) in September, highlight the potential for ADV7103 to get the very first strategy to dRTA, a kidney orphan disease rich in unmet medical needs.”

Dr Granier added, “Our strong links to key opinion leaders in nephrology, alongside our development expertise and scientific understanding happen to be answer to the effective clinical growth and development of ADV7103. The Advicenne team’s focus continues to be driven by their unwavering dedication to deliver pediatric-friendly therapeutics to patients to treat orphan kidney illnesses that you will find presently no approved treatments.Inch

The poster titled “Safety and effectiveness of ADV7103, a cutting-edge prolonged-release dental alkalising combination product, after 6-several weeks treatment in distal kidney tubular acidosis (dRTA) patients” was presented at ASN on second November 2017. The abstract could be utilized here.

About distal Kidney Tubular Acidosis (dRTA) 

dRTA is really a disease that happens when the kidneys don’t correctly remove acids in the bloodstream in to the urine. Consequently, an excessive amount of acidity remains within the bloodstream which generates an unbalanced pH that can result in failure to thrive and rickets (a disorder that affects bone rise in children) in addition to a selection of additional clinical disorders like a potassium deficiency (hypokalaemia) within the bloodstream serum which alters the part of countless organs and many conspicuously affects the heart. Additionally, a higher power of calcium within the bloodstream and urine (hypercalcemia and hypercalciuria) can result in kidney gemstones and calcinosis that may potentially cause kidney impairment, ultimately resulting in kidney failure. The condition, either genetic (usually occurring during childhood) or acquired because of autoimmune disease, is believed to affect roughly 30,000 patients in Europe and 20,000 in america. Current standard of care are often various unapproved products administered every 4 to 6 hrs to try to re-balance your body’s pH and also to normalise bloodstream potassium level.

About Advicenne 

Advicenne is really a late-stage pharmaceutical company concentrating on the introduction of pediatric-friendly therapeutics to treat orphan kidney and nerve illnesses. The Business’s innovative method is ADV7103 that has proven positive produces a pivotal phase III study in adults and children with distal Kidney Tubular Acidosis (dRTA). ADV7103 may also be coded in another indication to treat Cystinuria, a hereditary kidney tubulopathy and it is expected to initiate a pivotal Phase II/III medical trial in 2018 in Europe.

Additionally to ADV7103, the organization includes a portfolio of clinical and pre-clinical products targeting critical unmet needs in nephrology and neurology together with Key Opinion Leaders.

The Organization started in 2007 in Nimes (France). Since its beginning, the organization has elevated near to €30 million in equity from leading investment capital investors Innobio (Bpifrance), IXO Private Equity Finance, IRDI SORIDEC Gestion, Cemag Invest and MI Care.

More information about Advicenne can be obtained through its website: world wide web.advicenne.com

Disclaimer  

This pr release contains specifics of clinical growth and development of ADV7103.

For more information, please contact:
Advicenne
LA Granier, S Delbaere, J Rachline
[email protected]
+33-()-4-66-05-54-20

Citigate Dewe Rogerson
David Dible, Sylvie Berrebi, Marine Perrier, Laurence Bault, Alexandre Dechaux
[email protected]
+44-()-20-7638-9571 / +33-()-1-53-32-78-87

SOURCE Advicenne

Luminex Corporation Reports Third Quarter 2017 Financial Results

AUSTIN, Texas, Oct. 30, 2017 /PRNewswire/ — Luminex Corporation (Nasdaq: LMNX) today announced financial results for the third quarter of 2017.  Financial and operating highlights for the quarter include the following:

  • Consolidated revenue of $74.1 million, an increase of 4% compared to the third quarter 2016.
  • Assay revenue was $37.9 million for the quarter ended September 30, 2017, representing a 17% increase over assay revenue for the third quarter of 2016.
  • Total sample-to-answer molecular product revenue of $11.9 million; growth of 55% compared to $7.7 million in the third quarter of 2016.
  • Placed 60 sample-to-answer molecular systems under contract, bringing the total number of active customers to over 400.
  • 266 multiplexing analyzers were shipped during the quarter; a combination of MAGPIX® systems, LX systems, and FLEXMAP 3D® systems.
  • GAAP net income of $17.6 million, or $0.40 per diluted share. Non-GAAP net income of $10.7 million, or $0.25 per diluted share (see Non-GAAP reconciliation).
  • In September, Luminex agreed to continue to provide a major customer with our Cystic Fibrosis product portfolio through the end of 2019, with an option to extend beyond this time period.

“The tremendous momentum in our sample-to-answer molecular business drove the Company’s performance this quarter. Our VERIGENE and ARIES systems are experiencing excellent traction in the market resulting from a combination of factors, including their ease of use, a rapidly expanding FDA cleared test menu, differentiated pricing strategies, and a large, fully integrated sales and support team,” said Homi Shamir, President and Chief Executive Officer of Luminex.  “We remain enthusiastic about our diversified business model, our solid balance sheet, positive cash flow profile, and the significant future growth opportunities in both our Licensed Technologies Group and our molecular diagnostics business.”

REVENUE SUMMARY

(in thousands, except percentages) 

Three Months Ended

September 30,

Variance

2017

2016

($)

(%)

(unaudited)

System sales

$           9,903

$         10,494

$       (591)

-6%

Consumable sales

10,619

12,305

(1,686)

-14%

Royalty revenue

11,001

11,068

(67)

-1%

Assay revenue

37,917

32,443

5,474

17%

Service revenue

2,894

2,934

(40)

-1%

Other revenue

1,802

1,977

(175)

-9%

$         74,136

$         71,221

$     2,915

4%

Nine Months Ended

September 30,

Variance

2017

2016

($)

(%)

(unaudited)

System sales

$         28,309

$         27,805

$        504

2%

Consumable sales

39,314

37,489

1,825

5%

Royalty revenue

33,375

33,888

(513)

-2%

Assay revenue

113,077

85,367

27,710

32%

Service revenue

8,594

7,892

702

9%

Other revenue

5,703

5,927

(224)

-4%

$       228,372

$       198,368

$    30,004

15%

FINANCIAL OUTLOOK AND GUIDANCE

The Company reaffirms its guidance for the full year and expects fourth quarter 2017 revenue to be between $76 million to $78 million.

CONFERENCE CALL

Management will host a conference call at 3:30 p.m. CDT / 4:30 p.m. EDT, Monday, October 30, 2017 to discuss the operating highlights and financial results for the third quarter 2017 ended September 30, 2017. The conference call will be webcast live and may be accessed at Luminex Corporation’s website at http://www.luminexcorp.com.  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call will be archived for six months on the website using the ‘replay’ link.

Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company’s xMAP® system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company’s xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex or xMAP can be obtained on the Internet at http://www.luminexcorp.com.

Statements made in this release that express Luminex’s or management’s intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding expected revenue and cost savings, projected 2017 performance, including revenue guidance, including the revenue contribution from our recently completed acquisition of Nanosphere, Inc. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “will,” “could,” “should” and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company’s actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.  Factors that could cause Luminex’s actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex’s products and technology in development, including ARIES®, Verigene®and NxTAG®products; dependence on strategic partners for development, commercialization and distribution of products; concentration of Luminex’s revenue in a limited number of direct customers and strategic partners, some of which may be experiencing decreased demand for their products utilizing or incorporating Luminex’s technology; budget or finance constraints in the current economic environment, or periodic variability in their purchasing patterns or practices as a result of material resource planning challenges; the timing of and process for regulatory approvals; the impact of the ongoing uncertainty in global finance markets and changes in governmental funding, including its effects on the capital spending policies of Luminex’s partners and end users and their ability to finance purchases of Luminex’s products; fluctuations in quarterly results due to a lengthy and unpredictable sales cycle; fluctuations in bulk purchases of consumables; fluctuations in product mix, and the seasonal nature of some of Luminex’s assay products; Luminex’s ability to obtain and enforce intellectual property protections on Luminex’s products and technologies; risks and uncertainties associated with implementing Luminex’s acquisition strategy, including Luminex’s ability to obtain financing; Luminex’s ability to integrate acquired companies or selected assets into Luminex’s consolidated business operations, and the ability to recognize the benefits of Luminex’s acquisitions; reliance on third party distributors for distribution of specific Luminex-developed and manufactured assay products; Luminex’s ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels; changes in principal members of Luminex’s management staff; potential shortages, or increases in costs, of components or other disruptions to Luminex’s manufacturing operations; competition and competitive technologies utilized by Luminex’s competitors; Luminex’s ability to successfully launch new products in a timely manner; Luminex’s increasing dependency on information technology to improve the effectiveness of Luminex’s operations and to monitor financial accuracy and efficiency; the implementation, including any modification, of Luminex’s strategic operating plans; the uncertainty regarding the outcome or expense of any litigation brought against or initiated by Luminex, risks relating to Luminex’s foreign operations, including fluctuations in exchange rates, tariffs, customs and other barriers to importing/exporting materials and products in a cost effective and timely manner; difficulties in accounts receivable collections; the burden of monitoring and complying with foreign and international laws and treaties; and the burden of complying with and change in international taxation policies, as well as the risks discussed under the heading “Risk Factors” in Luminex’s Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.  The forward-looking statements, including the financial guidance and 2017 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

LUMINEX CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

September 30,

December 31,

2017

2016

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents

$        110,911

$         93,452

Accounts receivable, net

36,432

32,365

Inventories, net

46,114

40,775

Prepaids and other

9,915

7,145

Total current assets

203,372

173,737

Property and equipment, net

57,686

57,375

Intangible assets, net

78,152

84,841

Deferred income taxes

45,943

42,497

Goodwill

85,481

85,481

Other

8,094

6,785

Total assets

$        478,728

$       450,716

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable

$            7,813

$         12,276

Accrued liabilities

21,175

22,804

Deferred revenue

5,123

5,120

Total current liabilities

34,111

40,200

Deferred revenue

1,609

1,875

Other

4,828

4,962

Total liabilities

40,548

47,037

Stockholders’ equity:

Common stock

43

43

Additional paid-in capital

345,663

336,430

Accumulated other comprehensive loss

(817)

(1,692)

Retained earnings

93,291

68,898

Total stockholders’ equity

438,180

403,679

Total liabilities and stockholders’ equity

$        478,728

$       450,716

LUMINEX CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2017

2016

2017

2016

(unaudited)

(unaudited)

Revenue

$     74,136

$     71,221

$    228,372

$    198,368

Cost of revenue

28,317

25,556

79,706

62,976

Gross profit

45,819

45,665

148,666

135,392

Operating expenses:

Research and development

10,670

12,762

35,350

35,324

Selling, general and administrative

26,454

26,393

78,604

70,942

Amortization of acquired intangible assets

2,166

2,482

6,689

5,797

Total operating expenses

39,290

41,637

120,643

112,063

Income from operations

6,529

4,028

28,023

23,329

Other income, net

(1)

30

(6)

(1,395)

Income before income taxes

6,528

4,058

28,017

21,934

Income tax benefit (expense)

11,085

(1,307)

4,371

(4,760)

Net income

$     17,613

$       2,751

$     32,388

$     17,174

Net income attributable to common stock holders

Basic

$     17,299

$       2,751

$     31,789

$     17,174

Diluted

$     17,299

$       2,751

$     31,789

$     17,174

Net income per share attributable to common stock holders

Basic

$         0.40

$         0.06

$         0.74

$         0.40

Diluted

$         0.40

$         0.06

$         0.74

$         0.40

Weighted-average shares used in computing net income per share

Basic

43,164

42,683

43,110

42,522

Diluted

43,266

43,136

43,216

42,929

Dividends declared per share

$         0.06

$         0.18

LUMINEX CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2017

2016

2017

2016

(unaudited)

(unaudited)

Cash flows from operating activities:

Net income

$     17,613

$       2,751

$     32,388

$     17,174

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

5,609

5,913

16,879

14,401

Stock-based compensation

3,829

3,526

8,577

8,181

Deferred income tax expense

(10,379)

1,540

(3,112)

4,471

Loss (gain) on sale or disposal of assets

417

87

417

128

Other

357

(799)

1,279

(870)

Changes in operating assets and liabilities:

Accounts receivable, net

(3,295)

(3,118)

(4,053)

3,555

Inventories, net

988

(2,125)

(5,316)

(6,165)

Other assets

(1,564)

(902)

(2,761)

(230)

Accounts payable

(2,163)

(1,674)

(4,532)

1,050

Accrued liabilities

2,273

(428)

(5,138)

(6,602)

Deferred revenue

81

112

(269)

733

Net cash provided by operating activities

13,766

4,883

34,359

35,826

Cash flows from investing activities:

Sales and maturities of available-for-sale securities

19,491

Purchase of property and equipment

(3,981)

(2,675)

(10,384)

(8,394)

Proceeds from sale of assets

1

42

1

45

Business acquisition consideration, net of cash acquired

(1,196)

(68,098)

Issuance of note receivable

(700)

(700)

Purchase of cost method investment

(500)

(1,000)

(500)

Acquired technology rights

(60)

(60)

(200)

Net cash used in investing activities

(4,740)

(4,329)

(12,143)

(57,656)

Cash flows from financing activities:

Payments on debt

(25,000)

Proceeds from issuance of common stock

1,005

1,799

3,234

3,561

Shares surrendered for tax withholding

(28)

(13)

(2,124)

(1,497)

Dividends

(2,645)

(5,281)

Net cash (used in) provided by financing activities

(1,668)

1,786

(4,171)

(22,936)

Effect of foreign currency exchange rate on cash

(152)

87

(586)

365

Change in cash and cash equivalents

7,206

2,427

17,459

(44,401)

Cash and cash equivalents, beginning of period

103,705

81,718

93,452

128,546

Cash and cash equivalents, end of period

$    110,911

$     84,145

$    110,911

$     84,145

LUMINEX CORPORATION

NON-GAAP RECONCILIATION

(in thousands)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2017

2016

2017

2016

(unaudited)

(unaudited)

Income from operations

$       6,529

$       4,028

$     28,023

$     23,329

Stock-based compensation

3,829

3,526

8,577

8,181

Amortization of acquired intangible assets

2,166

2,482

6,689

5,797

Acquisition costs

479

2,487

Severance costs

243

126

901

940

Adjusted income from operations

$     12,767

$     10,641

$     44,190

$     40,734

Other income, net

(1)

30

(6)

(1,395)

Acquisition costs

1,500

Income tax expense

11,085

(1,307)

4,371

(4,760)

Income tax effect of above adjusting items

(761)

(305)

(2,053)

(721)

Income tax benefit from discrete tax items

(12,400)

(12,400)

Adjusted net income

$     10,690

$       9,059

$     34,102

$     35,358

Adjusted net income per share, basic

$         0.25

$         0.21

$         0.79

$         0.83

Shares used in computing adjusted net income per share, basic

43,164

42,683

43,110

42,522

Adjusted net income per share, diluted

$         0.25

$         0.21

$         0.79

$         0.82

Shares used in computing adjusted net income per share, diluted

43,266

43,136

43,216

42,929

The Company makes reference in this release to “non-GAAP net income” which excludes stock-based compensation expense, amortization of acquired intangible assets and the impact of costs associated with legal proceedings; some of which are unpredictable and can vary significantly from period to period; and certain other recurring and non-recurring expenses. The Company believes that excluding these items and their related tax effects from its financial results reflects operating results that are more indicative of the Company’s ongoing operating performance while improving comparability to prior periods, and, as such may provide investors with an enhanced understanding of the Company’s past financial performance and prospects for the future. In addition, the Company’s management uses such non-GAAP measures internally to evaluate and assess its core operations and to make ongoing operating decisions. This information is not intended to be considered in isolation or as a substitute for income from operations, net income, net income per share or expense information prepared in accordance with GAAP.

View original content with multimedia:http://www.prnewswire.com/news-releases/luminex-corporation-reports-third-quarter-2017-financial-results-300545678.html

SOURCE Luminex Corporation

Related Links

http://www.luminexcorp.com

Steer clear of the madness: It’s here we are at health data to go in the twenty-first century

craziness, insane,

Imagine you’re in the checkout counter inside a supermarket. Following the cashier rings up all of your groceries, you insert your bank card in to the nick-and-pin machine and also the cashier hands a pen along with a clipboard with a few densely worded documents. “Please read and finish these forms, then sign and initial where indicated to authorize this transaction,” he states.

Presuming you need to do as requested and also the individuals line behind you haven’t began to riot, the cashier then informs you that the authorizations is going to be joined in to the system and you’ll be notified in 5 to 7 working days whenever your transaction is finished as well as your groceries could be released for you, one more thing, you may even need to re-shop for your products in those days.

Sounds a little insane, doesn’t it?

But this is actually the same process most us citizens encounter once they utilize health or medical services. Based on Reuters, “Less than one out of three U.S. hospitals will find, send, and receive emr for patients who receive care elsewhere.” Citing research conducted recently printed within the Health Matters policy journal (Progress In Interoperability: Calculating US Hospitals’ Engagement In Discussing Patient Data), Reuters reports that “to compensate, patients frequently obtain copies of records they deliver personally for an outdoors provider or ask that they be sent.” What when you undergo this kind of ordeal any time you desired to purchase something together with your bank card or transfer funds involving the accounts or make use of an ATM?

“Because EHRs” or “Because HIPAA” are typical excuses with this Kafkaesque condition of matters.

However the ’90s-era Healthcare Insurance Portability and Accountability Act (HIPAA) was signed into law to enhance the digitalization and portability of insurance coverage and safeguard health data integrity, confidentiality, and availability. How could this type of noble effort result in this type of bureaucratic nightmare?

Based on Past the HIPAA Privacy Rule, a consensus study report printed through the National Development of Sciences, “HIPAA is built to achieve two primary goals: To create healthcare delivery more effective and also to increase the amount of Americans with insurance coverage. One of the ways it was accomplished was by developing a standard for electronic health records. This permitted patients to alter doctors, leave jobs, switch insurance, etc., without unnecessary documents. But HIPAA also made health records readily available, which brought to some greater requirement for privacy laws and regulations, so attendant privacy rules were suggested through the Department of Health insurance and Human Services (HHS),” that have been adopted.

It appears everything found a screeching halt.

While almost all US hospitals have finally adopted electronic health records, the Matters study noted that “hospitals’ progress toward interoperability is slow which progress is centered on moving information between hospitals, this is not on making certain usability of knowledge in clinical decisions.” Reuters reported that the most typical barrier to inter-hospital health information use “was their clinicians couldn’t view it embedded to their own system’s electronic health record.”

Ideas reach the crux from the issue. While patient information is clearly incredibly sensitive and privacy and security have the most concern, it’s not EHRs or HIPAA which are holding things back.

Everything could be digitalized and privacy-protected, however the information needs to be both exchangeable and functional to allow the type of immediate access we obtain with this financial services. And also to enable that, we ought to gain knowledge from the financial services sector, which transformed an identical problem years back.

During the early 1970s, Telex was the only real available method for banking institutions to verify worldwide funds transfers. Based on the London School of Financial aspects, a “transaction would frequently require exchange in excess of ten Telex messages, which made the procedure pricey and time-consuming. Authentication procedures needed to guarantee the necessary degree of to safeguard fund transfers were also complex and elevated labor intensity. To create things difficult, Telex messages appeared to be transmitted by means of free text allowing you to transmit payment instructions in a variety of formats.”

Not too efficient, could it be?

To deal with the problem, The Society for Worldwide Interbank Financial Telecommunication (Quick) was created in 1974 to supply a network that enables global banking institutions to receive and send details about financial transactions via a system of codes inside a secure, standardized and reliable atmosphere. Within 3 years of introduction, “SWIFT membership had elevated to 230 banks across five countries…Its success is related to the way it constantly adds new message codes to deliver different financial transactions…The sturdiness from the message format design permitted huge scalability through which Quick progressively expanded to supply services.”

Nowadays there are 11,000+ member institutions situated in 200+ countries and territories which is utilized by banks, brokerages, securities dealers, asset managers, treasury market players, and a number of other participants within the financial services ecosystem.

I am not proposing that Quick can easily be overlaid on the health system and also the problem is going to be solved. Healthcare includes its very own unique constraints and factors. But we all do hold the technology to apply an identical model, which most definitely can and really should be used. Just like Quick, it might quickly provide the type of data liquidity so clearly essential for modernizing our medical and health services. It’s time for you to steer clear of the madness. Addressing the origin of the issue is the initial step toward mitigating it, and can free our overall health systems to operate because they should within the 21st century.

Photo: Getty Images

Kx Selected by BrainWaveBank because the Platform for that World’s First Big Data Assortment of Brainwave Activity

LONDON, October 23, 2017 /PRNewswire/ —

  • Kx technology to aid BrainWaveBank because it uses AI to change cognitive health  
  • Solutions according to Kx allows visitors to monitor their cognitive health insurance and allow BrainWaveBank to build up systems able to screening for early indications of conditions for example Alzheimers disease –  
  • Using AI, the woking platform will analyse large datasets to analyse causal results of cognitive decline and help in the introduction of drugs and therapies inside a market worth $8 billion by 2021  

Global technology specialist FD announces that BrainWaveBank, a cutting-edge start-up centered on cognitive health, has selected Kx technology to power its neuroscience platform. The agreement allows BrainWaveBank to construct the earth’s first Big Data assortment of brainwave activity data and also to concentrate on the cognitive health assessment market, likely to achieve USEight Dollars.1 billion in 2021, based on analysts MarketsandMarkets.

     (Emblem: http://mma.prnewswire.com/media/519591/Kx_Emblem.digital )

Presently, 90% of people that are afflicted by cognitive health disorders are diagnosed a long time far too late or by no means and also the incidence of Alzheimer’s alone is anticipated to triple to 130 million people by 2050. It’s believed that early recognition and intervention can delay start of the condition and lower the price of care by 35% or even more. BrainWaveBank’s solution, produced by a group of neuroscientists, cognitive psychologists, machine learning and large data analytics specialists, would be to supply the ability for people to trace their very own cognitive performance – and analyse it for anomalies relative to their personal background and the information generated by other users inside their demographic.

To do this BrainWaveBank is promoting an inexpensive, high definition brainwave (EEG) checking headset that may be worn in your own home while playing engaging mobile games for any couple of minutes each day, several occasions each week. The information could be adjusted for factors for example medication, sleep and activity and also the aggregated information is accustomed to establish healthy baselines for various census. In addition to monitoring individual cognitive health, BrainWaveBank also promises to address the £800m per year marketplace for medical trial support, helping pharma companies to recognize trial candidates for drugs directed at the first stages of neurodegenerative illnesses.

Kx perseverence the neuroscience platform that analyses the information, that will build in to the world’s first database of brainwave activity recorded daily in your home. Using Kx allows real-time analytics to become conducted on brainwave activity and can accelerate analysis of aggregated data.

Ronan Cunningham, Ceo of BrainWaveBank commented: “Through being able to quickly process huge amounts of time-series data, provide analytics in tangible-time, and integrate with this machine learning pipelines, Kx is ideally placed to power our neuroscience platform. Additionally, it is able to scale seamlessly to aid our intend to produce the largest and many valuable database of EEG data, tagged with demographic, behavioural and lifestyle information, which has have you been put together.”

John Conlon, Ceo of Kx commented: “BrainWaveBank is brought by experienced computational neuroscience and cognitive psychology experts having a business development guide that is capable of doing transforming the way in which cognitive health is measured and treated. Mixing this domain expertise with this Kx technology can deliver new insights within this important section of healthcare.”

About Kx 

Kx is really a division of FD, a worldwide technology provider with 20 experience dealing with a few of the world’s largest finance, technology, retail, pharma, manufacturing and institutions. Kx technology, incorporating the kdb+ time-series database, is really a leader in high-performance, in-memory computing, streaming analytics and operational intelligence. Kx delivers the perfect performance and versatility for top-volume, data-intensive analytics and applications across multiple industries. The Audience operates from 14 offices across Europe, The United States and Asia Off-shore, including its headquarters in Newry, and employs greater than 1,800 people worldwide.

To learn more about Kx check out http://world wide web.kx.com. For general queries, email [email protected]

About BrainWaveBank 

BrainWaveBank’s goal would be to build the earth’s largest assortment of brain activity data to aid a change within the recognition and management of cognitive illness. Specifically-designed games and innovative brain-studying technologies measure subtle alterations in cognitive performance, while machine learning methods decode these tracks to provide new insights into the way your brain works. BrainWaveBank’s technology enables anybody to determine and track their cognitive health in your own home in a couple of minutes each day, helping transform our knowledge of brain health to ensure that people can live longer, healthier lives.

To learn more about BrainWaveBank visit http://world wide web.brainwavebank.com

SOURCE Kx

An upswing from the hybrid operating room

Recent advancements in heart valves and non-invasive surgery technology have led the way for more patients to be eligible for a endovascular/interventional procedures.  Yet these patients usual to very complex health conditions and therefore are at a bad risk for poor outcomes. In order to improve these poor outcomes and accommodate surgeon and interventionist needs, many hospitals have implemented hybrid operating rooms (typically an OR having a fixed C-arm angiographic system), and much more are thinking about it.

Hybrid ORs include steep cost tags—some could cost greater than $two million. Add-on another $3 million or even more for that appropriate OR equipment, integration systems, and facility renovation costs, as well as your project may now cost north of $5 million.

Cardiac surgeons clearly have an interest in hybrid ORs. But exactly how can a medical facility make sure that other physicians, their support staff and senior hospital/system leadership will also be involved in the look of the very complex set-up?

Advertisement

Every effective project begins with an positively engaged foundational team. A hybrid OR project team will include vascular, neurovascular, and cardiothoracic surgeons interventional cardiologists interventional radiologists OR nursing staff cath lab nursing staff and also the radiology technicians from both cath lab and interventional radiology. Participation through the IT team is important, as they’ll be key personnel within the integration of apparatus booms, the system’s table, and also the video monitors. The biomedical engineering department should participate this initial team too — they’ll be the “first responders” whenever there is a technical glitch. Finally, administrative leaders in the surgical, cardiac, and radiology departments have to be aboard as volume projections should be made and Finance needs to be engaged to find out when the cost could be justified.

Managing this large team is challenging because of so many different opinions and interests to think about.  Each clinical niche has somewhat unique needs requiring specific equipment placements.  While room sketches from various suppliers are useful, just the most adept clinical user generally is able to imagine the things they mean for the planned space. The Two-dimensional AutoCAD sketches a designer might develop throughout the planning stages are difficult to interpret if you’re not accustomed to studying them. While 3-dimensional and REVIT models tend to be more helpful compared to 2-D ones, a real live space—or a mock-up—really enables clinicians to know the spatial relationships a lot more clearly.  

Among the best methods to observe how hybrid ORs operate in actual practice would be to visit clinical sites where they’re presently installed and talk to frontline staff regarding their specific challenges. Ask users the way they altered the room’s configuration when new clinical services started while using room. Explore the way they manage consumable supplies where they’re stored. Where are their video monitors placed? What are the limitations because of the size the area? Did they select a floor-mounted or perhaps a ceiling-mounted C-arm? Why? Ask why they selected their unique angiographic system and just how they coordinated the different installation efforts. Additionally to any or all your fact-finding, you have to keep the Chief executive officer, COO, along with other leadership up-to-date together with your progress. This generally is one of the biggest capital expenses of the season, as well as in some hospitals it might be the biggest from the decade.

In the end the very fact-finding and installation challenges, your hybrid Or perhaps is almost ready. Before it’s fully operational, conduct some role-playing exercises to make sure that staff are very well experienced in how things works prior to the very first official hybrid procedure. You might want OR staff to look at a cath procedure as well as for cath lab staff to look at an OR procedure. Slight variations – or really major differences—in practice can make cause a lot of confusion when staff expectations are included a hybrid OR.  Make sure credentialing and quality criteria have established yourself.  

When the hybrid Or perhaps is finally under way, monitor surgeon and interventionalist usage—monitor “actual” versus “projected” in the amount of procedures to make sure that goals are met.  

With the right planning, a hybrid OR benefits both patients as well as your hospital’s performance. You might be so effective you need to start throughout again—with planning for a second hybrid OR.

Photo: Simonkr, Getty Images 

Israeli medtech firm elevated $15M to deal with heart-failure patients with catheter-based therapy

Acute heart failure affects about 6.5 million individuals the U . s . States, with 960,000 new cases diagnosed yearly, according to data in the American Heart Association.

Executives at Israel-based Green Medical think that their catheter-based therapy can prevent lots of heart failure-related hospital admissions that derive from fluid build-up that burdens the center and kidneys.

Founded in October 2012 with a cardiologist along with a mechanical engineer, Green Medical elevated $15 million a week ago. Investors include medical device company Abiomed Pitango Investment Capital, an Israeli fund JAFCO, a Japanese private equity finance firm, and several cardiac experts including Jacques Seguin, a cardiac surgeon, inventor, and entrepreneur.

For individuals away from the know, Seguin was the founding father of CoreValve, which Medtronic bought in excess of $700 million in ’09. Medtronic sells various iterations of the transcatheter aortic valve substitute device to deal with diseased heart valves.

“The proven fact that [these investors] find curiosity about what we should do is significant,”  stated David Israeli, the previous chairman of Green Medical and it is current Chief executive officer, inside a phone interview.

Their technology includes a flow pump that’s placed around the venous side and enables the kidneys to boost or optimize function to get rid of salt, Israeli described.

Contrast by using the present approach to treating fluid-buildup noticed in heart failure patients when their ankles increase the size of or once they put on weight suddenly: diuretics. But individuals frequently result in high rates of failing kidney function and hospital readmissions, Israeli stated.

Green Medical’s technologies are already in numerous studies in Europe and also the funds will be accustomed to win CE Mark. The information from individuals European trials will probably be distributed to Food and drug administration to look for the company’s regulatory approach within the U.S.

“With our current funding, hopefully to achieve agreement using the Food and drug administration around the clinical path within the U . s . States,” Israeli stated.

The unit provides therapy for approximately 24 hrs and doesn’t have bid farewell to a lasting implant. Israeli stated their technology is also likely to lead to savings towards the healthcare system. Many heart-failure patients notice a big loss of how their kidneys function and frequently finish in the ICU.

“We need to prove that, and we’re visiting a signal for the reason that direction,” Israeli stated, adding he expects the device can prevent complications that will eliminate the requirement for the ICU.

Photo: Abscent84, Getty Images

A ” new world ” of non-invasive cardiac diagnostics

heart, doctor, cardiac

Toronto-based Analytics 4 Existence just elevated $25 million in Series B financing to build up and eventually commercialize their non-invasive cardiovascular diagnostic. The unit, known as CorVista, reads electrical signals in the heart and, after some AI assistance, converts them into images to assist clinicians assess cardiovascular damage. To some extent, we’ve got the technology is customized from brain surgery.

“Our founding researcher (Sunny Gupta) was investigating signal processing for missile defense,” stated President and Chief executive officer Don Crawford inside a phone interview. “He was taking signals from the 1000 miles away and working out the things they originate from – plane, balloon, missile? If he could identify signals, he could use the same technology towards the body. He centered on the center because it’s a huge electro-mechanical pump.”

CorVista is noninvasive, requires no drugs, radiation or stress testing. Clinicians place seven sensors around the patient, which collect ten million data points within three minutes. The information is distributed towards the cloud, examined and delivered back as three-dimensional images physicians can interpret.

Advertisement

“Heart cells under stress produce different frequencies and amplitudes,” stated Crawford. “As energy moves with the heart, it moves differently through regions of ischemia or disease. We’re searching at one-millionth of the volt in variations. This is where the device-learned formula is necessary.Inches

Analytics 4 Existence is performing a medical trial using more than 2,000 patients at 13 sites. “We should summary the trial prior to the finish of the season and file using the Food and drug administration within the first quarter of the coming year, stated Crawford.”

Over the border, near Cincinnati, Genetesis takes an identical, noninvasive method of discovering cardiovascular disease, searching for an easy method to eliminate cardiac occasions.

“The standard of care is EKG, serial bloodstream troponins, but you have really low negative predictive values using these tests,” stated co-founder and Chief executive officer Peeyush Shrivastava inside a phone interview. “The population health signifies 75 % of those cases aren’t cardiac. However with these low negative predictive tests, physicians aren’t always confident ruling out cardiac-origin chest discomfort.”

The primary problem is that the patient have a myocardial infarction soon after they leave a healthcare facility. At the moment, the answer is to see the patient with time, possibly days, use them a treadmill for stress testing or conduct a catheterization procedure.

“Where our technology matches is there exists a through the roof negative predictive value,” stated Shrivastava, “giving physicians the opportunity to eliminate cardiac-origin chest discomfort, very rapidly, with no invasiveness.”

The Genetesis device, known as CardioFlux, requires more infrastructure than CorVista, together with a shielded chamber to remove magnetic sources. The sensors don’t touch the individual, so no prep is needed, and also the scan takes around a minute. Algorithms convert the magnetic data into maps that highlight coronary heart, particularly ischemia.

To date, we’ve got the technology has gotten some high-profile endorsements, including seed round funding from Mark Cuban and CincyTech. The organization is collecting clinical data and wants Food and drug administration clearance sometime the coming year.

“Innovative technology is needed,” stated Shrivastava. “Not just incremental enhancements but something which can definitely stand the ages to resolve an open health burden the size of that one.Inches

Photo: John A Jackson, Getty Images